Exagen Q3 revenue up 7% to $18.4M, guides FY2026 at $72M-$75M
Exagen reported third-quarter revenue of $18.4 million, with year-to-date growth of 11% and an improved net loss. The company reaffirmed full-year 2026 revenue guidance of $72 million to $75 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed